A Relative Bioavailability Study of Single-dose, Randomized, Open-label, Single-period, Parallel Design of HRS9531 Injection Using Different Manufacturing Processes in Healthy Subjects
Latest Information Update: 27 Oct 2023
At a glance
- Drugs HRS 9531 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Fujian Shengdi Pharmaceutical
Most Recent Events
- 22 Oct 2023 Status changed from recruiting to completed.
- 12 Jun 2023 New trial record
- 08 Jun 2023 Status changed from not yet recruiting to recruiting.